Advanced Oncotherapy PLC (LON:AVO) subsidiary ADAM S.A. Executive Chairman professor Steve Myers talks to DirectorsTalk about the LIGHT system, it’s likely impact, the design, the progress being made and its..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today the appointment of Dr. Jonathan Farr as Senior Vice-President of Medical Physics with immediate..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that it has made further progress in attracting personnel at the forefront of their..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today further notable progress in the manufacture of its first LIGHT system. Patient Positioning System..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that excavation work at its flagship Harley Street site is progressing well and on..
Advanced Oncotherapy plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of..
Michel Baelen, head of Regulatory Affairs at Advanced Oncotherapy plc (LON:AVO), talks to DirectorsTalk about the attraction of joining AVO, his past roles and how this experience benefits the company,..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that Dr Nick Plowman, Non-Executive Director, will invest £250,000 in the Company. The investment..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that further to the notification on 22 February 2017, the Company has drawn down..
Following the new appointment at Advanced Oncotherapy Plc (LON:AVO) as Senior Independent Non-Executive Director, Mr Hans von Celsing talks to DirectorsTalk about his past experience, the present and his thoughts..
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an..
Advanced Oncotherapy Plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, will be hosting investor an analyst presentations in Zürich, Switzerland Tuesday 7 March 2017. The..
Advanced Oncotherapy plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, announced today that further to the financing agreement with Bracknor announced on 22 February 2017,..
Advanced Oncotherapy PLC (LON:AVO) Chief Executive Officer Nicholas Serandour & Bracknor Investment Group Chief Executive Officer Pierre Vannineuse caught up with DirectorsTalk for an exclusive interview to discuss their £26..
Advanced Oncotherapy plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, announced today that it has secured a flexible and staged £26 million financing agreement (the..
Advanced Oncotherapy Plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, announced today that it will be hosting investor and analyst presentations in London on Monday..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today the appointment of Dr Nick Plowman, Senior Clinical Oncologist at St Bartholomew’s Hospital (“Barts”)..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 that Dr Nick Plowman, Chairman of the..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today the appointment of Professor Steve Myers OBE and Mr Hans von Celsing as Non-Executive..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that, in September 2016, it commenced discussions concerning a proposal it had received from..
